According to a study highlighted in GI & Hepatology News, a therapeutic vaccine combined with low-dose chemotherapy converted pancreatic ductal adenocarcinomas into immunogenic cancers that may respond to immunotherapy. In the study, the therapeutic vaccine combined with low-dose chemotherapy primed almost 85 percent of pancreatic ductal adenocarcinomas to potentially respond to immunotherapy.

READ FULL ARTICLE Curated publisher From Gastro